One of the highlights of Eli Lilly's third-quarter ... and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling ... In terms of achieving the highest alpha, owning the stock for two years may be the shrewdest ...
It fell last week after the company released updated guidance, with revenue for its GLP-1 ... Eli Lilly's stock is off to a tough start in 2025, and it could continue that way unless ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The ...
Eli Lilly (NYSE:LLY) shares sold off on Tuesday ... Citing preliminary unaudited financials, LLY said that sales from its GLP-1 products, Mounjaro and Zepbound, indicated for diabetes and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback